Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early chemotherapy switching and PD-L1 inhibitor strategy in neoadjuvant triple-negative breast cancer
ChiCTR2000029565Phase 3Not yet recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Aug 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of docetaxel, paclitaxel, pirarubicin, epirubicin, cyclophosphamide and 1 more in breast cancer and triple-negative breast cancer (TNBC) (2 arms), sponsored by Shenzhen Second People's Hospital. Primary endpoints: Vital signs, Complete blood count and 4 more. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
docetaxelpaclitaxelpirarubicinepirubicincyclophosphamide
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2000029565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029565.